Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About CFP Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About CFP Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
Research ArticlePractice

Effectiveness of riboflavin in pediatric migraine prevention

Michelle Sherwood and Ran D. Goldman
Canadian Family Physician March 2014, 60 (3) 244-246;
Michelle Sherwood
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ran D. Goldman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

Abstract

Question The rate of migraine diagnosed among children is increasing. Is riboflavin, an alternative to traditional pharmacologic agents, effective and safe for prevention of migraine in children?

Answer Because migraine is a very common condition in childhood and adolescence, often contributing to substantial burden of illness, there is increased interest in alternatives to traditional pharmacologic prevention. The expectation is that over-the-counter alternative medication will be less toxic, better tolerated, and have fewer side effects. A few studies in adults show that riboflavin (vitamin B2) might decrease frequency of migraine headaches. It has become common practice to recommend that children try riboflavin to prevent migraine; however, research on riboflavin use in children is inconclusive.

More than 11% of children 5 to 15 years old and 28% of adolescents 15 to 19 years old suffer from migraine, and most of them will seek medical consultation at least once during childhood.1 The prevalence of migraine increases with age; it is slightly higher in boys before puberty and 1.5 times more frequent in girls in adolescence.2 Childhood migraine might result in increased school absences, compromised academic performance, and decreased participation in extracurricular activities.

Diagnosis of migraine in childhood is challenging and the condition can be classified with or without aura. The International Classification of Headache Disorders, 3rd edition, is the current criterion standard for diagnosis.3 Migraine is defined as a recurrent headache disorder with at least 5 attacks that last 4 to 72 hours with at least 2 of the following features: unilaterality, throbbing sensation, moderate to severe intensity, or aggravation by physical activity.3 Photophobia and phonophobia, as well as nausea with or without vomiting, are also among the diagnostic criteria.3

Slight modifications have been made to the criteria for pediatric populations: migraines might be bilateral, they can be shorter in duration, and some autonomic features such as photophobia and phonophobia can be inferred from the child’s behaviour. The younger the child, the less characteristic the symptoms; however, by adolescence, presentation should meet adult-based criteria.3 As in adults, comorbidities such as mood, anxiety, sleep, and eating disorders might occur.4

Treating migraine

Acetaminophen, ibuprofen, ergot alkaloids, and intranasal triptans are frequently used to treat acute migraine attacks.5 To abort the migraine soon after it begins, 15 mg/kg of acetaminophen or 10 mg/kg of ibuprofen have been shown to be equally effective.6 Of the triptans (5-hydroxytryptamine agonists), sumatriptan nasal spray (5 and 20 mg) has been shown to be most effective for relieving adolescent headaches.5 Delayed gastric emptying and nausea can accompany migraines, but there are limited studies to support treatment with antiemetics.

Many patients find keeping a headache journal helpful to try and establish a pattern and determine provoking factors.5 Long-term management of migraine relies on lifestyle changes (eg, adopting sleep hygiene, exercising, avoiding triggers such as caffeine, eating regular meals, maintaining hydration, and managing stress), as well as early treatment to prevent chronicity.5

Migraine prevention

With frequent or intense migraines, preventive measures might be necessary to improve quality of life and avoid overuse of medications such as acetaminophen and ibuprofen.7 Topiramate (100 mg/d) has been shown to be effective in decreasing the frequency of pediatric migraine attacks, but study results with amitriptyline, propranolol, and flunarizine have been contradictory or inconclusive.4 Other preventive options include cyproheptadine, gabapentin, pregabalin, valproate, amitriptyline, nortriptyline, and verapamil, each with their own efficacies and side effects.4

Complementary therapies

With limited effectiveness of current preventive therapies, the use of complementary and alternative medicine has been increasing in headache management.8 Mitochondrial dysfunction has been postulated to play a role in migraine pathophysiology.9 Riboflavin is a precursor in the mitochondrial electron transport chain and a cofactor in the Krebs cycle, and has been used in various mitochondrial diseases—hence the hypothesis that increasing riboflavin availability might improve brain mitochondrial function and result in migraine prevention.10

Riboflavin in adults

Two randomized controlled trials with high-dose riboflavin (400 mg/d) had conflicting results.11,12 When riboflavin was compared with placebo in 55 adult patients, riboflavin reduced the frequency of migraine attacks (P = .005) and the number of headache days (P = .012).11 When riboflavin was given with magnesium and feverfew to 120 patients (from 2 different suburban hospitals) who were between 18 and 65 years of age and who had had migraine for at least 1 year, there was no difference between the experimental group and the placebo group in reduction of migraines (P = .87) or reduction of migraine days (P = .63).12 Of interest, 60% of patients dropped out of the study and there was a very high placebo response, possibly related to the fact that the placebo contained 25 mg of riboflavin.12

Riboflavin in children

Evidence for use of riboflavin in children is very limited. One retrospective study reported decreased migraine frequency in younger patients and decreased intensity in male patients.13 Among 41 Italian children (8 to 18 years of age) who received either 200 or 400 mg/d of riboflavin for 3, 4, or 6 months, riboflavin reduced migraine frequency (21.7 [SD 13.7] vs 13.2 [SD 11.8]; P<.01), particularly in children younger than 12 years old, and decreased intensity (2 [SD 0.5] vs 1.6 [SD 0.8]; P<.01) predominantly in boys (P<.05).13 Most (77%) patients reported that while taking riboflavin, their regular migraine-relieving medications (primarily nonsteroidal anti-inflammatory drugs, acetaminophen, and triptans) were more effective. The long duration of treatment and the follow-up period were considered the strengths of the study, but the retrospective design and small sample size limited the generalizability of the results.

Two randomized double-blind placebo-controlled trials reported no difference in reduction of migraines with use of riboflavin.14,15 Among 48 Australian children (5 to 15 years old) who were treated daily for 12 weeks with 200 mg of riboflavin, there was no significant difference in the number of migraine attacks over 4 weeks when compared with those receiving placebo.14 Severity of migraines (self-rating) was also similar between groups.

In a 2010 randomized double-blind placebo-controlled trial, 42 children from the Netherlands who were 6 to 13 years old received 50 mg/d of riboflavin for 16 weeks, followed by a 4-week break and 16 weeks of placebo or vice versa.15 The investigators found no significant difference in the mean frequency (P = .44), duration (P = .15), or severity (P = .18) of migraines between groups.15 Interestingly, there was a significant reduction in tension headaches (P<.04) reported by those in the riboflavin group.

Safety considerations of riboflavin

Riboflavin was well tolerated in all studies and there were no reports of serious toxicity.13 Riboflavin absorption has been shown to reach saturation at 30 to 50 mg and the half-life is approximately 1 to 2 hours.16 Dosing of 100 to 400 mg/d of riboflavin in the pediatric studies has been based on previous adult studies and doses used in mitochondrial diseases.10,13 This is approximately 100-fold higher than normal dietary intake.13 In both adult and pediatric riboflavin studies, there have been only limited reports of diarrhea, orange-coloured urine, and vomiting.

Conclusion

Despite being safe, well tolerated, and inexpensive, riboflavin does not show effectiveness in preventing migraine in children, and is not currently recommended for that indication. There seem to be sex and age differences in response to riboflavin,13 possibly owing to differences in pharmacokinetics and riboflavin serum levels.17 Research with a larger sample size is needed in order to control for placebo response. Administering riboflavin with food or in multiple daily dosing was previously suggested.17 Pharmacogenetic studies are ongoing, and there might be certain haplotypes of mitochondria that respond to riboflavin more readily.18

If a provider decides that the child should try riboflavin, the recommended dose should be 50 to 400 mg/d for a minimum of 4 months. If there is no improvement, riboflavin should be discontinued and pharmacologic prevention should be considered. Providers should ensure that children continue to receive appropriate migraine treatment, suggest the use of a headache journal, and advise patients and families about lifestyle changes.

Notes

PRETx

Child Health Update is produced by the Pediatric Research in Emergency Therapeutics (PRETx) program (www.pretx.org) at the BC Children’s Hospital in Vancouver, BC. Dr Sherwood is a member and Dr Goldman is Director of the PRETx program. The mission of the PRETx program is to promote child health through evidence-based research in therapeutics in pediatric emergency medicine.

Do you have questions about the effects of drugs, chemicals, radiation, or infections in children? We invite you to submit them to the PRETx program by fax at 604 875-2414; they will be addressed in future Child Health Updates. Published Child Health Updates are available on the Canadian Family Physician website (www.cfp.ca).

Footnotes

  • This article is eligible for Mainpro-M1 credits. To earn credits, go to www.cfp.ca and click on the Mainpro link.

  • La traduction en français de cet article se trouve à www.cfp.ca dans la table des matières du numéro de mars 2014 à la page e157.

  • Competing interests

    None declared

  • Copyright© the College of Family Physicians of Canada

References

  1. 1.↵
    1. Split W,
    2. Neuman W
    . Epidemiology of migraine among students from randomly selected secondary schools in Lodz. Headache 1999;39(7):494-501.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Abu-Arafeh I,
    2. Razak S,
    3. Sivaraman B,
    4. Graham C
    . Prevalence of headache and migraine in children and adolescents: a systematic review of population-based studies. Dev Med Child Neurol 2010;52(12):1088-97. Epub 2010 Sep 28.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. International Headache Society
    . The international classification of headache disorders, 3rd edition (beta version). Cephalalgia 2013;33(9):629-808.
    OpenUrlFREE Full Text
  4. 4.↵
    1. Jacobs H,
    2. Gladstein J
    . Pediatric headache: a clinical review. Headache 2012;52(3):333-9. Epub 2012 Jan 30. Erratum in: Headache 2012;52(3):527.
    OpenUrlPubMed
  5. 5.↵
    1. Lewis DW,
    2. Yonker M,
    3. Winner P,
    4. Sowell M
    . The treatment of pediatric migraine. Pediatr Ann 2005;34(6):448-60.
    OpenUrlPubMed
  6. 6.↵
    1. Hämäläinen ML,
    2. Hoppu K,
    3. Valkeila E,
    4. Santavuori P
    . Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled, crossover study. Neurology 1997;48(1):103-7.
    OpenUrlCrossRef
  7. 7.↵
    1. Gaul C,
    2. Eismann R,
    3. Schmidt T,
    4. May A,
    5. Leinisch E,
    6. Wieser T,
    7. et al
    . Use of complementary and alternative medicine in patients suffering from primary headache disorders. Cephalalgia 2009;29(10):1069-78. Epub 2009 Apr 2.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Schetzek S,
    2. Heinen F,
    3. Kruse S,
    4. Borggraefe I,
    5. Bonfert M,
    6. Gaul C,
    7. et al
    . Headache in children: update on complementary treatments. Neuropediatrics 2013;44(1):25-33. Epub 2013 Jan 11.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Montagna P,
    2. Cortelli P,
    3. Monari L,
    4. Pierangeli G,
    5. Parchi P,
    6. Lodi R,
    7. et al
    . 31P-magnetic resonance spectroscopy in migraine without aura. Neurology 1994;44(4):666-9.
    OpenUrlCrossRef
  10. 10.↵
    1. Sparaco M,
    2. Feleppa M,
    3. Lipton RB,
    4. Rapoport AM,
    5. Bigal ME
    . Mitochondrial dysfunction and migraine: evidence and hypotheses. Cephalalgia 2006;26(4):361-72.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Schoenen J,
    2. Jacquy J,
    3. Lenaerts M
    . Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 1998;50(2):466-70.
    OpenUrlCrossRef
  12. 12.↵
    1. Maizels M,
    2. Blumenfeld A,
    3. Burchette R
    . A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. Headache 2004;44(9):885-90.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Condò M,
    2. Posar A,
    3. Arbizzani A,
    4. Parmeggiani A
    . Riboflavin prophylaxis in pediatric and adolescent migraine. J Headache Pain 2009;10(5):361-5. Epub 2009 Aug 1.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. MacLennan SC,
    2. Wade FM,
    3. Forrest KM,
    4. Ratanayake PD,
    5. Fagan E,
    6. Antony J
    . High-dose riboflavin for migraine prophylaxis in children: a double-blind, randomized, placebo-controlled trial. J Child Neurol 2008;23(11):1300-4.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Bruijn J,
    2. Duivenvoorden H,
    3. Passchier J,
    4. Locher H,
    5. Dijkstra N,
    6. Arts WF
    . Medium-dose riboflavin as a prophylactic agent in children with migraine: a preliminary placebo-controlled, randomised, double-blind, crossover trial. Cephalalgia 2010;30(12):1426-34. Epub 2010 Mar 26.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Zempleni J,
    2. Galloway JR,
    3. McCormick BD
    . Pharmacokinetics of orally and intravenously administered riboflavin in healthy humans. Am J Clin Nutr 1996;63(1):54-66.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. O’Brien HL,
    2. Hershey AD
    . Vitamins and paediatric migraine: riboflavin as a preventative medication. Cephalalgia 2010;30(12):1417-8. Epub 2010 Jul 27.
    OpenUrlFREE Full Text
  18. 18.↵
    1. Di Lorenzo C,
    2. Pierelli F,
    3. Coppola G,
    4. Grieco GS,
    5. Rengo C,
    6. Ciccolella M,
    7. et al
    . Mitochondrial DNA haplogroups influence the therapeutic response to riboflavin in migraineurs. Neurology 2009;72(18):1588-94.
    OpenUrlCrossRef
View Abstract
PreviousNext
Back to top

In this issue

Canadian Family Physician: 60 (3)
Canadian Family Physician
Vol. 60, Issue 3
1 Mar 2014
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Effectiveness of riboflavin in pediatric migraine prevention
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
Citation Tools
Effectiveness of riboflavin in pediatric migraine prevention
Michelle Sherwood, Ran D. Goldman
Canadian Family Physician Mar 2014, 60 (3) 244-246;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Effectiveness of riboflavin in pediatric migraine prevention
Michelle Sherwood, Ran D. Goldman
Canadian Family Physician Mar 2014, 60 (3) 244-246;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Treating migraine
    • Migraine prevention
    • Complementary therapies
    • Riboflavin in adults
    • Riboflavin in children
    • Safety considerations of riboflavin
    • Conclusion
    • Notes
    • Footnotes
    • References
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

  • Efficacité de la riboflavine dans la prévention de la migraine pédiatrique
  • Scopus
  • PubMed
  • Google Scholar

Cited By...

  • Appui au developpement professionnel continu
  • Supporting continuing professional development
  • Scopus (6)
  • Google Scholar

More in this TOC Section

Practice

  • Management of gastroesophageal reflux disease in pediatric patients with cerebral palsy
  • Colorectal cancer screening for patients with a family history of colorectal cancer or adenomas
  • Palliative care in patients with severe mental illness
Show more Practice

Child Health Update

  • Management of gastroesophageal reflux disease in pediatric patients with cerebral palsy
  • Time-to-effect of fluoxetine in children with depression
  • Duct tape for warts in children
Show more Child Health Update

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • RSS Feeds

Copyright © 2019 by The College of Family Physicians of Canada

Powered by HighWire